Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present \>/= 1 month by history or exam~* BCVA is worse than 20/200 at time of screening~Exclusion Criteria:~* Corneal or lenticular abnormalities that preclude fundus observation~* Ongoing ocular infection, inflammation or history of herpetic corneal lesion~* Current or prior retinal detachment or retinal tears or breaks or intraocular tumor~* More than 1 severe vitreous hemorrhage within 6 months~* Previous vitrectomy for any reason~* Hemorrhage is exclusively pre-retinal, or old \& organized~* Prior Vitrase for intravitreal injection in either eye~* No light perception in either eye at any time~* Known contraindications to study medication~* Sickle cell disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitrase (Type: EXPERIMENTAL): Single Hyaluronidase ophthalmic intravitreal injection
- Placebo (Type: PLACEBO_COMPARATOR): Single Saline solution intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).